NANOMEDICAL SOLUTIONS
POP Biotechnologies develops next generation platform technologies to address unmet medical needs in oncology and infectious disease
NEWS
ONCOLOGY
VACCINES
February 24, 2021
POP Biotechnologies (POP BIO) announces the commencement of first-in-human studies of SARS-CoV-2 vaccine in collaboration with South Korean vaccine manufacturer Eubiologics Co., Ltd. (Eubiologics).
The vaccine candidate, called EuCorVac-19, is a liquid injection that can be stored and distributed at refrigerated temperatures, potentially making it easier to distribute and store than some current vaccines which must be frozen.
The first phase will involve 50 healthy adults in Korea to evaluate the safety, tolerance and immune response to the vaccine. For the second phase, the number of participants will increase to 230 adults to further evaluate immune response and dosage. The goal is to begin a wide-scale phase 3 trial later this year.
ONCOLOGY
POP BIO’s light-activated nanoparticle drug delivery system, PhotoDOX, is an innovative cancer therapy designed to address solid tumors which resist current standards of care, such as cutaneous metastatic breast cancer (CMBC), liver cancer (hepatocellular carcinoma, HCC), and pancreatic cancer (PaCa).
PhotoDOX combines POP BIO’s porphyrin-phospholipid (PoP) liposome with the widely prescribed anti-cancer drug doxorubicin (Dox) to provide localized drug release with enhanced therapeutic benefit when activated by light.
PhotoDOX provides precise targeting of Dox to tumor sites in combination with a chemotherapy with the precision of light-based treatments.
VACCINES
The SNAP vaccine platform technology is a unique nanoparticle system that incorporates a revolutionary approach to vaccine development, functioning as a potent vaccine adjuvant.
The SNAP platform provides a unique binding mechanism enabling the efficient, rapid, and stable binding of one or more vaccine antigens to its surface, forming vaccine candidates with a markedly greater immune response compared to existing adjuvants.
Like a conventional vaccine adjuvant, the SNAP technology can be mixed with antigens just prior to vaccination-- making the SNAP approach a stockpileable strategy against emerging diseases, bioterrorism, or pandemics. Unlike typical vaccine adjuvants, the resulting antibody responses are orders of magnitude higher due to the stable, high-density antigen presentation to the immune system.